{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:17Z","timestamp":1790186537589,"version":"4.1.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamaophthalmol.2022.1091","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:01:47Z","timestamp":1655377307000},"page":"771","source":"Crossref","is-referenced-by-count":24,"title":["Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"140","author":[{"given":"Margaret A.","family":"Chang","sequence":"first","affiliation":[{"name":"Retinal Consultants, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Kapre","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Kardatzke","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Rabena","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shienal","family":"Patel","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Bobbala","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Gune","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fung","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Wallenstein","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi220022r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220022r2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration.","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"eoi220022r3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study.","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"eoi220022r4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/OPTH","article-title":"Current barriers to treatment for wet age-related macular degeneration (WAMD): findings from the WAMD patient and caregiver survey.","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"eoi220022r5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"issue":"4","key":"eoi220022r6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi220022r7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"eoi220022r8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial.","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi220022r9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration.","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi220022r10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","article-title":"End-of-study results for the Ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration.","volume":"5","author":"Khanani","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"eoi220022r11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/PROM","article-title":"The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice.","volume":"10","author":"Braithwaite","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"eoi220022r12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/bjophthalmol-2016-309955","article-title":"\u201cThe patient is speaking\u201d: discovering the patient voice in ophthalmology.","volume":"101","author":"Dean","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"eoi220022r13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/PPA","article-title":"Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting.","volume":"10","author":"Gohil","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"eoi220022r14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41687-018-0031-z","article-title":"Design and development of the MacTSQ measure of satisfaction with treatment for macular conditions used within the IVAN trial.","volume":"2","author":"Mitchell","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"eoi220022r15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cpr.2014.06.002","article-title":"Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis.","volume":"34","author":"Lindhiem","year":"2014","journal-title":"Clin Psychol Rev"},{"issue":"10","key":"eoi220022r16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"eoi220022r17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"eoi220022r21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2020-000669","article-title":"Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): development of a patient-reported measure to assess treatment burden of repeat intravitreal injections.","volume":"6","author":"McClard","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"issue":"10","key":"eoi220022r22","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","article-title":"Systematic review: non-adherence and non-persistence in intravitreal treatment.","volume":"258","author":"Ehlken","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"eoi220022r23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/eye.2016.18","article-title":"Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis.","volume":"30","author":"Baxter","year":"2016","journal-title":"Eye (Lond)"},{"key":"eoi220022r24","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.2147\/OPTH.S273564","article-title":"Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema.","volume":"14","author":"Bhagat","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"eoi220022r25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","article-title":"Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment.","volume":"123","author":"Mueller","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi220022r26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-013-2412-6","article-title":"Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration\u2014monthly injections versus pro re nata.","volume":"252","author":"Droege","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"eoi220022r27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/11206721211001716","article-title":"Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: results of the AMD-MANAGE study.","volume":"32","author":"Pina Mar\u00edn","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"eoi220022r28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/PPA.S239196","article-title":"Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment.","volume":"14","author":"McNamara","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"eoi220022r29","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1007\/s00520-021-06230-9","article-title":"Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.","volume":"29","author":"Metz","year":"2021","journal-title":"Support Care Cancer"},{"key":"eoi220022r20","author":"Tschosik","year":"2019"},{"key":"eoi220022r18","unstructured":"World Medical Association. WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. Accessed September 3, 2021. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"},{"key":"eoi220022r19","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised guideline integrated addendum to ICH E6(R1): guideline for Good Clinical Practice ICH E6(R2) ICH consensus guideline. Accessed September 3, 2021. https:\/\/ichgcp.net\/"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2793387\/jamaophthalmology_chang_2022_oi_220022_1660767210.76617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:06:33Z","timestamp":1660907193000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2793387"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.1091","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}